| EPD051 | HIV stigma among people living with HIV in Uganda: a psychometric evaluation and a framework test of the HIV Stigma Mechanism Scale | E-poster | Strengthening social and behavioural data collection and analysis |
| EPA058 | Rufinamide-induced autophagy cell death in HIV-1-infected macrophages | E-poster | Strategies to reduce/eliminate viral reservoirs |
| EPA059 | Effect of novel latency reversal agents on transposable element expression profile in T-cell memory subsets of HIV clinical samples | E-poster | Strategies to reduce/eliminate viral reservoirs |
| EPA060 | Off-target effects on retroelement expression in T-cells Treated with Histone deacetylase inhibitors | E-poster | Strategies to reduce/eliminate viral reservoirs |
| EPA061 | Nanoparticle delivery of romidepsin to reverse HIV latency | E-poster | Strategies to reduce/eliminate viral reservoirs |
| EPA062 | Gamma/Delta T cells target latently HIV-infected non-T cell reservoirs | E-poster | Strategies to reduce/eliminate viral reservoirs |
| OAA0102 | Pharmacological enhancement of IL-15 signaling to improve 'shock-and-kill' strategies against latent HIV | Oral abstract session with live Q&A | Strategies to reduce/eliminate viral reservoirs |
| OAA0305 | SARS-CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T cells | Oral abstract session with live Q&A | Strategies to reduce/eliminate viral reservoirs |
| OAA0403 | In vivo preclinical efficacy of MGD014 and MGD020 (HIV-1 envelope x CD3 DART molecules) and first-in-human phase 1 clinical safety evaluation of MGD014 | Oral abstract session with live Q&A | Strategies to reduce/eliminate viral reservoirs |
| OAA0404 | AZD5582 and SIV Env-targeting rhesus monoclonal antibodies (RhmAbs) ± N-803 in SIV-infected ART-suppressed rhesus macaques | Oral abstract session with live Q&A | Strategies to reduce/eliminate viral reservoirs |